973 related articles for article (PubMed ID: 32697281)
1. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
[TBL] [Abstract][Full Text] [Related]
5. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
8. First-line immunotherapy versus targeted therapy in patients with
Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
[No Abstract] [Full Text] [Related]
9. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
Li SN; Wan X; Peng LB; Li YM; Li JH
BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
[TBL] [Abstract][Full Text] [Related]
11. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
[TBL] [Abstract][Full Text] [Related]
12. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract][Full Text] [Related]
13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
14. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
16. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
17. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Specenier P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
[No Abstract] [Full Text] [Related]
19. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Tarhini A; Benedict A; McDermott D; Rao S; Ambavane A; Gupte-Singh K; Sabater J; Ritchings C; Aponte-Ribero V; Regan MM; Atkins M
Immunotherapy; 2018 Oct; 10(14):1241-1252. PubMed ID: 30175642
[TBL] [Abstract][Full Text] [Related]
20. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
